| |
|
 |
 |
 |
 |
| |
 |
 |
Professor Molly Stevens
m.stevens@imperial.ac.uk
|
| |
Molly Stevens is currently Professor of Biomedical Materials and Regenerative Medicine and the Research Director for Biomedical Material Sciences in the Institute of Biomedical Engineering.
She joined Imperial in 2004 after a Postdoctoral training in the field of tissue engineering with Professor Robert Langer in the Chemical Engineering Department at the Massachusetts Institute of Technology (MIT). Prior to this she graduated from Bath University with a first class honours degree in Pharmaceutical Sciences and was then awarded a PhD in biophysical investigations of specific biomolecular interactions and single biomolecule mechanics from the Laboratory of Biophysics and Surface Analysis at the University of Nottingham (2000). In 2009 she was awarded the Jean Leray Award from the European Society for Biomaterials, in 2007 the prestigious Conference Science Medal from the Royal Pharmaceutical Society and in 2005 the Philip Leverhulme Prize for Engineering. She has also recently been recognised by the TR100, a compilation of the top innovators, under the age of 35, who are transforming technology - and the world with their work. Her previous awards include the Ronald Belcher Memorial Lecture Award from the Royal Society of Chemistry (2000) and both the Janssen Prize and the UpJohn Prize for academic excellence and research.
She has a large and extremely multidisciplinary research group of students and postdocs/fellows. Research in regenerative medicine within her group includes the directed differentiation of stem cells, the design of novel bioactive scaffolds and new approaches towards tissue regeneration. She has developed novel approaches to tissue engineering that are likely to prove very powerful in the engineering of large quantities of human mature bone for autologous transplantation as well as other vital organs such as liver and pancreas, which have proven elusive with other approaches. This has led to moves to commercialise the technology (she is the co-founder of BioCeramic Therapeutics and InTiGen) and set-up a clinical trial for bone regeneration in humans. In the field of nanotechnology the group has current research efforts in exploiting specific biomolecular recognition and self-assembly mechanisms to create new dynamic nano-materials, biosensors and drug delivery systems. |
|
|
 |
 |
|
 |
 |
|
| |
|
 |
|
| |
|
|
| |
 |
| |
 |
 |
 |
 |
| |
 |
 |
Miss Melissa Bovis
UROP student in Stevens' Group in 2007 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
 |
 |
Mr James Liew
Exchange Student in Stevens' Group in 2008-2009 conducting research project into Protease Detection based on Microcantilever Array Technology in collaboration with the London Centre for Nanotechnology |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
 |
 |
Mr Michael Losak
Summer student from Yale conducting research project into electrospun scaffolds for tissue regeneration
|
|
|
 |
 |
 |
 |
 |
|
|
 |
 |
 |
 |
| |
 |
 |
Dr Silvia Goldoni
Post-Doctoral Research Associate in Stevens’ Group since 2010 investigating cell signalling regulated by mechano-sensing of substrates and scaffolds for tissue engineering.
Previously:
Research Assistant Professor, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, USA
Post-Doctoral Fellow, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, USA studying the role of the extracellular matrix proteoglycan decorin in tumour growth and its potential as a therapeutic against malignancies.
Doctor in Medical Biotechnology, Universita’ di Modena, Italy
|
|
|
 |
 |
 |
 |
 |
|
| |
 |
| |
|
| |
 |
| |
|
|
|
 |